Classify this DEFA14A as procedural — no change to investment thesis. Monitor the June 18 annual meeting for any unexpected voting outcomes, but no trading catalyst from this supplement alone. The CEO succession was previewed in the May 28 8-K and this filing merely formalizes it for proxy purposes.
Price Chart
Executive Summary
Allogene Therapeutics filed a DEFA14A supplementing its 2026 proxy statement to disclose the CEO transition from David Chang to Zachary Roberts, effective July 1, 2026. The filing is a routine procedural update for the upcoming June 18 annual meeting, confirming existing proxy cards remain valid and no new voting matters are introduced.
Key Financial Metrics
Key Facts
- CEO transition from David Chang to Zachary Roberts effective July 1, 2026
- Dr. Roberts will receive $680,000 base salary, 60% target bonus, options for 476,190 shares, and 134,530 RSUs
- Dr. Chang will remain on Board as non-employee director after June 30, 2026
- Annual meeting of stockholders remains scheduled for June 18, 2026
- Existing proxy cards unchanged; no new voting matters
Financial Impact
CEO severance for Chang under existing plan and new CEO compensation package totaling ~$680K salary plus equity grants — immaterial relative to ~$777M market cap
Risk Factors
- No material risk identified from this procedural filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-245501 |
| Document: 0001193125-26-245501-index-headers.html | 0001193125-26-245501 |
| Document: 0001193125-26-245501-index.html | 0001193125-26-245501 |
| Document: 0001193125-26-245501.txt | 0001193125-26-245501 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 144 | $1.25 $1.25 | · 0.00% | ▲ +0.52% | $1.23 (−1.92%) |
Sep 2, 2026 7w ago | 8-K | $1.98 $1.98 | · 0.00% | ▼ −1.05% | $1.23 (−38.08%) |
Aug 21, 2026 9w ago | 144 | $2.03 $2.17 | ▲ +6.90% | ▲ +6.58% | $1.23 (−39.61%) |
Aug 21, 2026 9w ago | EFFECT | $2.09 $2.03 | ▲ +2.87% | ▲ +2.58% | $1.23 (+41.34%) |
Aug 6, 2026 11w ago | Institutional Cluster | $1.97 $2.01 | ▲ +2.03% | ▲ +1.42% | $1.23 (−37.77%) |
Jun 22, 2026 18w ago | 8-K | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.23 (+40.77%) |
Jun 22, 2026 18w ago | 424B5 | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.23 (+40.77%) |
May 28, 2026 21w ago | DEFA14A | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.23 (−43.50%) |
May 28, 2026 21w ago | 8-K | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.23 (−43.50%) |
May 28, 2026 21w ago | Press Release | $2.17 $2.15 | ▼ −0.92% | ▼ −1.20% | $1.23 (−43.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers